A drug developed in St. Louis is beginning human trials with the idea of helping those most at risk of dying from COVID-19. ATI-450 was originally developed by Confluence Discovery Technologies in 2013 as a treatment for autoimmune diseases, particularly rheumatoid arthritis. Confluence co-founder Joe Monahan discusses with host Sarah Fenske how it might now also help with the new coronavirus -- and what it will take to bring it to market.
